Schwartz Gary L, Turner Stephen T
Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA.
Clin Chem. 2005 Feb;51(2):386-94. doi: 10.1373/clinchem.2004.041780.
The ratio of plasma aldosterone concentration to plasma renin activity (PRA) is considered the screening test of choice for primary aldosteronism. Uncertainty exists, however, regarding its diagnostic accuracy and the effects of antihypertensive drugs and dietary sodium balance on test characteristics.
We measured PRA and aldosterone in 118 white adults [71 men and 47 women; mean (SD) age, 51 (7) years] with previously diagnosed essential hypertension. Measurements were made while individuals were on antihypertensive drug therapy, after a 2-week drug-free period, after 4 days of dietary sodium loading, and after acute furosemide diuresis. We measured 24-h urine aldosterone excretion and PRA on the 4th day of dietary sodium loading to establish the diagnosis of primary aldosteronism. ROC curves were constructed for ratios measured under each clinical condition, and likelihood ratios were determined for individuals on or off antihypertensive drug therapy.
Fifteen patients [13%; 95% confidence interval (CI), 7-20%] met the reference standard for primary aldosteronism. The mean (SD) areas under the ROC curves did not differ significantly across conditions of measurement [range, 0.80 (0.10) to 0.85 (0.04); P = 0.72]. When measured on and off antihypertensive drug therapy, the 95% CIs for the optimum cutpoint for the ratio overlapped. Point estimates of sensitivity on and off therapy were 73% (95% CI, 50-96%) and 87% (70-100%), respectively, and specificities were 74% (65-83%) and 75% (66-84%). Under either condition, increased ratios were associated with 2.4- to 13-fold increases of posttest odds above pretest odds.
The aldosterone:PRA ratio provides only fair diagnostic accuracy in screening for primary aldosteronism, but concomitant antihypertensive drug therapy or acute variation in dietary sodium balance does not adversely affect test accuracy. Reporting of likelihood ratios associated with ranges of values of the aldosterone:PRA ratio, rather than use of a single "optimum" cutpoint, may enhance the usefulness of the test.
血浆醛固酮浓度与血浆肾素活性(PRA)的比值被认为是原发性醛固酮增多症的首选筛查试验。然而,其诊断准确性以及抗高血压药物和饮食钠平衡对试验特征的影响尚不确定。
我们对118名先前诊断为原发性高血压的白人成年人[71名男性和47名女性;平均(标准差)年龄,51(7)岁]测量了PRA和醛固酮。测量在个体接受抗高血压药物治疗时、停药2周后、饮食钠负荷4天后以及急性速尿利尿后进行。我们在饮食钠负荷第4天测量24小时尿醛固酮排泄和PRA以确立原发性醛固酮增多症的诊断。为每种临床情况下测量的比值构建ROC曲线,并确定接受或未接受抗高血压药物治疗个体的似然比。
15名患者[13%;95%置信区间(CI),7 - 20%]符合原发性醛固酮增多症的参考标准。ROC曲线下的平均(标准差)面积在不同测量条件下无显著差异[范围,0.80(0.10)至0.85(0.04);P = 0.72]。在接受和未接受抗高血压药物治疗时测量,该比值的最佳切点的95%CI重叠。治疗时和未治疗时敏感性的点估计分别为73%(95%CI,50 - 96%)和87%(70 - 100%),特异性分别为74%(65 - 83%)和75%(66 - 84%)。在任何一种情况下,比值升高与试验后比试验前的比值增加2.4至13倍相关。
醛固酮:PRA比值在筛查原发性醛固酮增多症时仅具有中等诊断准确性,但同时进行的抗高血压药物治疗或饮食钠平衡的急性变化不会对试验准确性产生不利影响。报告与醛固酮:PRA比值范围相关的似然比,而非使用单一的“最佳”切点,可能会提高该试验的实用性。